Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Return on Sales (2016 - 2025)

IGC Pharma has reported Return on Sales over the past 16 years, most recently at 0.1% for Q3 2025.

  • Quarterly Return on Sales fell 5.0% to 0.1% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 0.06% through Sep 2025, up 5.0% year-over-year, with the annual reading at 0.06% for FY2025, 4.0% up from the prior year.
  • Return on Sales was 0.1% for Q3 2025 at IGC Pharma, down from 0.05% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.04% in Q1 2025 and troughed at 0.78% in Q3 2021.
  • The 5-year median for Return on Sales is 0.1% (2024), against an average of 0.18%.
  • The largest YoY upside for Return on Sales was 72bps in 2021 against a maximum downside of -64bps in 2021.
  • A 5-year view of Return on Sales shows it stood at 0.17% in 2021, then soared by 60bps to 0.07% in 2022, then tumbled by -304bps to 0.27% in 2023, then soared by 74bps to 0.07% in 2024, then crashed by -34bps to 0.1% in 2025.
  • Per Business Quant, the three most recent readings for IGC's Return on Sales are 0.1% (Q3 2025), 0.05% (Q2 2025), and 0.04% (Q1 2025).